冠心病介入治疗后有无肝素方案对临床预后的影响

被引:2
作者
高传玉
黄克钧
沈玉祥
Patracia Fox
Rob Whitboun
高恩民
李俊秀
朱中玉
李牧尉
张嘉莹
张静
周晗
徐予
牛振民
陈岩
机构
[1] 河南省人民医院
[2] 澳大利亚墨尔本StVincent医院
关键词
冠状动脉支架; 静脉肝素应用; 缺血并发症; 出血并发症; 临床预后;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
摘要
目的 :探讨冠状动脉支架置入术后是否应用肝素对临床预后的影响。方法 :1998年 10月~ 2 0 0 1年 10月 2 40 0例行冠状动脉支架术病人在鞘管拔出后按用或不用静脉肝素方案分为两组。对两组病人住院期间和 3 0d缺血事件和出血并发症的影响进行回顾性分析。结果 :肝素组住院期间缺血并发症低于无肝素组 ,缺血并发症减少 5 8% (3 70 %vs9.10 % ,P <0 0 0 5 ) ,QMI减少 75 % (0 2 9%vs 1.2 0 % ,P <0 0 2 5 ) ,NQMI减少 65 % (1 5 0 %vs 4.3 5 % ,P <0 .0 0 5 ) ,靶血管再PTCA减少 78% (0 91%vs 4.10 % ,P <0 0 0 5 ) ,3 0d靶血管再梗死率降低 75 % (0 3 4%vs 1.40 % ,P <0 0 1) ;两组间出血并发症未见明显区别 (6 0 0 %vs 5 .10 % ,P >0 2 5 ) ;进一步分析发现 ,隔夜肝素组和 3d肝素组缺血和出血并发症也无明显区别 (2 0 0 %vs 3 .90 % ,P >0 10和 5 .89%vs 7.14 % ,P >0 .5 0 )。结论 :冠状动脉支架术后常规应用肝素能减少住院期间和 3 0dQMI、NQMI、靶血管再PTCA的发生率和亚急性血栓形成。延长静脉应用肝素不能进一步改善病人的缺血并发症 ,但也不增加出血的可能性
引用
收藏
页码:161 / 163
页数:3
相关论文
共 8 条
[1]  
Anticoagulation in interventional cardiology: optimizing patient outcome. Rutsch W,Baumann G. European Heart Journal . 1998
[2]  
Intimatan prevents arterial and venous thrombosis in canine model of deep vessel wall injury. Hennan JK,Hong TT,Shergill AK,et al. Journal of Pharmacology and Experimental Therapeutics . 2002
[3]  
Current perspectives on British use of adjunctive therapies during coronary interventions. Swanson N,Hogrefe K,Stephens Lioyd A,Gershlick A. International Journal of Cardiology . 2001
[4]  
A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease.Benestent Study Group. Serruys P,Dejaegere P,Keimeneij F,et al. The New England Journal of Medicine . 1994
[5]  
Local delivery of hydrophobic heparin reduces neointimal hyperplasia after balloon injury in rat carotid but not pig coronary arteries. Sasseen BM,Gray BD,Gal D,et al. Journal of Cardiovascular Pharmacology . 2001
[6]  
A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease.Stent Restenosis Study Investigators. Fishman DI,Leon MB,Baim DS,et al. The New England Journal of Medicine . 1994
[7]  
Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. Whittingham HA,Tsui W,Cheena AH,et al. Journal of the American College of Cardiology . 2002
[8]  
Ticlopidine and asprin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. Gregorini L,Marco J,Fajadet J,et al. Journal of the American College of Cardiology . 1997